EGFR and hypertensive disorder: The most common adverse events were rash (n = 9, 37.5%), diarrhea (n = 6, 25.0%) related to EGFR–TKI and hypertension (n = 6, 25.0%) related to anlotinib, followed by transaminase elevation (n = 4, 16.7%) and fatigue (n = 4, 16.7%).